RE Reuters Ascletis Pharma Submits Two IND Applications To U.S. FDA For Obesity Treatment 6/7/2026, 09:29 am GMT+8 Reuters 16 1672 Sources Reuters Markets Stocks Active symbols HKEX:1672 Language English (India) Ascletis Pharma Inc HKEX:1672: Ascletis Pharma Inc HKEX:1672:SUBMITS TWO IND APPLICATIONS TO U.S. FDA FOR OBESITY TREATMENT Market News PR Newswire Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35